ABSTRACT Hepatocellular carcinoma remains a leading cause of cancer death worldwide. There are an increasing number of patients that do not meet traditional criteria for surgical resection as a result of historically poor outcomes. We define these oncologically high-risk patients as those with either one of these risk factors or a combination of them: large ([5 cm) primary tumors, multinodular disease, and/or major vascular invasion. With appropriate selection and preparation, long-term survival is possible in this subset of patients after resection. This review focuses on the surgical treatment of these high-risk patients, focusing on our own institution's approach and methods as well as reviewing the literature pertinent to the support of our current practice.
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, and in some parts of the world, such as sub-Saharan Africa and Southeast Asia, HCC is the most common cancer overall. The varying incidence of HCC in different countries depends on the prevalence of the major causes. Such causes include chronic infection with hepatitis B virus, which itself is responsible for [50% of all cases of HCC; chronic infection with hepatitis C virus; chronic liver disease with subsequent cirrhosis that results from alcohol use; hemochromatosis; alpha-1-antitrypsin deficiency; and rare metabolic disorders. There is also a large population of noncirrhotic patients with HCC of uncertain etiology.
Various treatment modalities have been applied to HCC depending on the stage of the disease and on the overall functional capacity of the noncancerous liver. These include local ablative therapies, such radiofrequency or cryoablation, regional transarterial infusion/embolization, external-beam radiotherapy, hepatic resection, orthotopic liver transplantation, and systemic chemotherapy. Historically, the only proven potentially curative therapy for HCC is surgical-either hepatic resection or liver transplantation. Liver transplantation is considered in patients with cirrhosis who have met previously established criteria; hepatic resection is considered as primary therapy in any patient with HCC who has a noncirrhotic liver, or selected patients with chronic liver disease with well-preserved liver function who are otherwise unsuitable for liver transplantation. 1 The selection criteria of patients who should undergo either aggressive resectional surgical therapy or transplantation has changed considerably on the basis of evolving data from major hepatobiliary centers. Furthermore, with advancing technology, newer modalities that once were only considered experimental and adjunctive are now used in selected patients. The evolution of radiofrequency ablation as a nonsurgical therapy (which has proven to be superior to other forms of ablative techniques) exemplifies this particular point, given its current use in the treatment of HCC: as a bridging therapy before liver transplantation, as a first-line treatment for patients with small HCC up to 2 cm, and as a promising therapy for recurrent and unresectable HCC. Data from a recent randomized, controlled trial suggest that radiofrequency ablation could be considered as an alternative treatment option for otherwise resectable HCC. However, this should be reserved for selected lesions up to 3 cm, because the data from that trial are inconclusive due to methodological limitations and there is no evidence of benefit from radiofrequency ablation for larger lesions that are otherwise resectable. 2 This review will focus on the surgical approach to the management of oncologically high-risk HCC with regard to formal hepatic resection. Our definition of high-risk HCC includes any one of the following that are considered surgically resectable with or without chronic liver disease: tumors[5 cm in diameter, multinodular disease, and major vascular invasion. We will not discuss nonsurgical therapies because there is no current credible evidence suggesting it is equal to or better than surgical resection in this subset of high-risk patients.
PATIENT SELECTION

Large HCC
Large HCC ([5 cm in diameter) are still common when the patient first seeks care, despite increasing use of ultrasound and alfa-fetoprotein screening in high-risk populations worldwide. These tumors typically manifest in the absence of underlying cirrhosis and can grow to a large size (10 cm) without symptoms. These larger tumors have historically been considered to be at high risk for intrahepatic or extrahepatic spread. Larger tumor size has been found to directly correlate with vascular invasion, which in itself has been associated with inferior outcomes. 3, 4 The other nonresectional treatment options previously mentioned are relatively contraindicated. Locoregional ablative therapies are not effective for particularly large tumors. Liver transplantation offers acceptable outcomes only in small, early lesions in those centers that follow the established Milan criteria or even the new extended University of California, San Francisco, guidelines as a result of previous poor results and high recurrence rates in far larger lesions and is thus an inappropriate use of limited donor resources. 1, 5 In addition, the considerable technical challenges associated with major resection of these massive cancers are well documented and are associated with higher perioperative complications such as heavy bleeding and tumor rupture. As a result, patients with larger tumors are often denied aggressive curative therapy, and certain groups have even advocated that large tumor size ([5 cm) be a contraindication to liver resection. 6 That being said, we do not consider size alone to be a contraindication to surgery because liver resection is the only viable option for patients with large HCC.
Earlier published large-series single-institutional studies looking at outcomes after resection in patients with HCC [5 cm in size reported modest 5-year overall survival after resection ranging from 16.7% to 33%. [7] [8] [9] [10] [11] [12] Most of these data were accumulated in earlier decades, before the advent of modern liver surgical techniques and other contemporary methods such as portal vein embolization (PVE). More modern data have challenged these outcomes, and in fact, resection of solitary large HCC without vascular invasion has been documented to result in favorable outcomes with 5-year survivals of [70% in selected cases. 13 A more recent report looking at resection in HCC classified as giant ([10 cm) found overall survival and 5-year disease-free survival to be 45% and 43%, respectively.
14 Although data from the International Cooperative Study Group on HCC looking at resection of HCC in [400 patients from several high-volume centers identified a worse overall 5-year survival (39% vs. 58%) when comparing large ([5 cm) to small (\5 cm) tumors, the perioperative outcomes were comparable to those of patients with small HCC. 15 Moreover, those survival outcomes compare well to those reported in the literature that used nonsurgical modalities for patients with similarly staged HCC. Furthermore, another series of 300 patients undergoing resection for HCC with tumors [10 cm in size reported perioperative mortality of 5%, with most of those patients (60%) undergoing major or extended hepatectomy, proving that although technically challenging, large HCC can be safely removed. 16 
Multinodular HCC
Multinodular HCC has traditionally been considered a contraindication to resection, as it is associated with a far worse prognosis than solitary tumors. As a result, multinodularity has been integrated into all known HCC staging and classification systems. The early literature would suggest that transplantation alone is the only modality that can offer long-term survival in patients with multinodular disease. 1, 17 Initial work looking at outcomes in patients after resection of multinodular HCC compared to solitary tumors identified that only up to 25% of patients with multinodular disease can experience long-term survival after resection. 4, 18 Another, more recent study assessing 599 patients undergoing hepatectomy for multinodular HCC revealed that the 3-and 5-year survival rates were 69.2% and 58.4% for single-tumor HCC, and 55.5% and 29.9% for multinodular HCC. 19 Thus, it is true that multinodularity does portend more advanced disease and subsequent worse prognosis. Given the limited supply of donors for transplantation, the high number of patients who do not meet transplantation criteria, and the fact that approximately 20% of transplant candidate patients drop out as a result of progression of disease while awaiting transplantation, offering formal liver resection as the only chance for cure is appropriate for most of these patients. We thus do not consider multinodularity a contraindication to resection.
Recent data have shown markedly better outcomes even in this cohort of high-risk patients. Analysis of our own multi-institutional database reveals that hepatic resection can be safely performed in patients with multinodular HCC, with an overall 5-year survival rate of 39%. 15 Another study looking at 126 patients with multinodular disease found 5-year overall survival of 58%. 20 In that series, at a major hepatobiliary center, although 5-year recurrence was high ([70%), at least 20% of those recurrences were in patients who were able to undergo repeat resection for even further improved survival of [70% at 3 years. Thus, in the era of modern surgical technique and appropriate patient selection, even multinodular disease is not a contraindication for formal liver resection.
Major Vascular Invasion
As previously stated, major vascular invasion is classically one of the most important poor prognostic factors attributed to HCC, associated with an increased risk of intrahepatic and systemic metastases. Major vascular invasion has been found to be an independent predictor of outcome after resection. 21, 22 Intrahepatic dissemination of the tumor via the portal circulation is thought to be the mechanism for many in-liver recurrences. Because ablative therapies, transplantation, and systemic chemotherapy have not been shown to offer any marked survival benefit, and because the natural history of untreated disease leads to death usually within months, surgical resection remains the only therapeutic option that may offer any survival benefit. 1, [23] [24] [25] Early reports and updated series from single institutions have proven the feasibility and oncologic appropriateness of resection in selected patients and have been able to stratify risk on the basis of the location of the portal vein tumor thrombus. 26 They reported 5-year overall survival of 63% and 46% in those without or with vascular invasion, respectively, and have subsequently shown that patients with invasion to the second or third peripheral portal vein branches had greatly improved survival than those with invasion to the main portal trunk, contralateral portal vein, or invasion to the first branches (right or left) portal vein. Although initial resection in these patients is almost universally associated with recurrence in most cases, secondary treatments for recurrence, either with repeat resection or locoregional therapy, have led to satisfactory survival rates. Others have even shown that major vascular invasion to first portal branches can be treated with transarterial chemoembolization (TACE) combined with subsequent hepatectomy, resulting in 42% overall survival in highly selected patients compared to 7% for those not undergoing resection. 27 Subsequent multicenter data, including our own, have confirmed that surgical resection of HCC with major vascular invasion can be performed relatively safely with an acceptable mortality of 5.9%, and in fact can lead to long-term survival in a small subset of patients that is far superior to nonsurgical therapy. 28 The concept of gross versus microscopic invasion is important. A recent study looking at a cohort of patients undergoing resection with subsequent vascular invasion confirmed earlier data and found overall survival differed with microscopic vascular invasion (*40%) versus gross vascular invasion (*20%), as expected. 29 However, they also subdivided those with microscopic invasion to invasion of vessels with a muscular wall as well as invasion to vessels of [1 cm from the primary tumor, both of which were independent predictors or recurrence and worse survival. Although major vascular invasion is not a formal contraindication to surgical resection, such surgery offers the possibility of marked benefit in selected patients although the procedure remains palliative for most.
PREOPERATIVE CONSIDERATIONS
Chronic Liver Disease
The majority of patients with HCC assessed at our institution have associated liver cirrhosis, which presents a major challenge to treatment. There exists a spectrum of disease from no fibrosis to nonbridging fibrosis to frank cirrhosis, with associated severe fibrosis/cirrhosis being an independent predictor of outcome after resection for HCC. 30 Because the presence of underlying liver disease influences the survival duration of patients undergoing hepatic resection for HCC, this suggests that cirrhosis, hepatitis activity, or degree of fibrosis may predispose patients to multicentric hepatocarcinogenesis by way of a field defect. 31, 32 In fact, death due to HCC is rare in longterm survivors after resection in the absence of fibrosis or cirrhosis, suggesting that late death due to HCC in patients resected with chronic liver disease is a result of new primary tumors developing in a precancerous liver. 33 Unfortunately, the preoperative sampling variability of fibrosis is a major limitation in the preoperative assessment of fibrosis via liver biopsy. 34 Patients with associated decompensated liver failure are more likely to die from progression of their liver disease than from HCC; treatment of this malignancy thus has to take into consideration the residual functioning liver reserve.
Our standard criteria for minor resection of HCC in patients with chronic liver disease are presented in Table 1 .
The presence of portal hypertension does not preclude minor hepatic resection for HCC at our institution. Data from 66 Child-Pugh A patients with portal hypertension undergoing resection revealed similar overall 5-year survival (40%) as well as similar mortality, morbidity, and transfusion rates compared to a cohort without portal hypertension. 35 Similarly, others have reproduced excellent results for Child-Pugh A patients with portal hypertension undergoing resection for HCC with a 5-year overall survival of 56%. 20 For those patients with liver disease requiring major liver resection, our selection criteria narrow, and we also consider preoperative PVE.
PVE
Hepatic surgery carries a risk of postoperative hepatic decompensation and should be undertaken only in units with expertise in liver resection and management of liver failure. The development of postoperative liver failure after resection is the greatest determinant of postoperative mortality and morbidity in those patients with chronic liver disease and/or cirrhosis. Preoperative assessment of liver function has been accomplished by numerous methodologies varying according to geographic region and according to individual surgeon preference in an effort to determine the functioning capacity of the future liver remnant (FLR). None has proven superior. As a result, techniques have been developed with the hope of improving function of the remaining liver parenchyma after resection.
The clinical observation that portal vein tumor infiltration results in ipsilateral hepatic atrophy and contralateral hepatic hypertrophy led to the first use of PVE in resection for HCC. 36 PVE reduces the risk of postoperative hepatic insufficiency by inducing atrophy of the embolized tumorbearing lobe with compensatory hypertrophy of the nonembolized FLR. In patients who are candidates for major hepatectomy, the FLR size can vary, and the safe minimal size for FLR is not well defined or universally accepted. Thus, estimation of total liver volume is necessary before major hepatic resection is considered, which may result in a small FLR leading to postoperative liver failure. Computed tomographic volumetry has been shown to accurately assess the extent of liver resection. 37 FLR volume (which is not compromised by tumor) is directly measured by computed tomographic three-dimensional reconstruction. Total liver volume is adequately calculated on the basis of body surface area, as we have previously proven and validated. 38, 39 This method allows for a uniform comparison of FLR volume before resection with or without preoperative PVE. At our institution, PVE is often considered in patients without liver disease with extensive tumors requiring extended resections or with patients with chronic liver disease requiring standard right hepatectomy. PVE should be considered in patients whose FLR is estimated to be \20% to 40% of total liver volume, although the minimal criteria are in flux. 37, 40 Furthermore, a considerable amount of data have emerged regarding the significance of the degree of hypertrophy after PVE to predict postoperative outcome; however, the specific cutoff values have not been universally accepted or defined. In our experience, [5% hypertrophy after PVE is predictive of a low postoperative morbidity and mortality, but this will require validation in further studies.
Our group recently reported results after hepatectomy for HCC in patients undergoing PVE compared to non-PVE. 41 Excluding perioperative deaths, overall survival rates at 3 and 5 years were 82% and 72%, respectively, in the PVE group and 63% and 54%, respectively, in the non-PVE group, which were not statistically different. Similarly, disease-free survival rates were not statistically significantly different, with 3-and 5-year disease-free survival of 56% and 56%, respectively, in the PVE group and 49% and 49%, respectively, in the non-PVE group. Although the overall postoperative complication rates were comparable between the PVE and non-PVE groups (24% vs. 36%, P = .33), there was a statistically higher rate of major complications in the non-PVE group (36% non-PVE vs. 10% PVE group, P = .028). There were no postoperative deaths in the PVE group and six deaths in the non-PVE group (P = .038), five of which were due to postoperative hepatic insufficiency leading to multiorgan failure, thus suggesting that PVE may indeed improve outcome. A more recent study from our own institution looking at [300 extended right hepatectomies in patients without chronic liver disease found that the incidences of postoperative liver insufficiency (34% vs. 12.5%) and death from liver failure (11% vs. 2.5%) were higher in those with smaller preoperative FLR (B20%) compared to those with preoperative FLR C20%. 40 Interestingly, postoperative liver insufficiency and attributed death were similar between patients with increases in FLR from B20% to C20% after PVE compared to patients with an initial FLR of C20%. These results suggest that PVE increases the safety of major hepatectomy without compromising long-term oncologic outcomes as well as potentially increasing the pool of potential candidates for curative liver resection.
There is no randomized, controlled study on PVE. However, the hypertrophy of the FLR induced by PVE in patients with chronic liver disease has been shown to greatly decrease the rate of postoperative complications in a prospective clinical trial. 42 In patients with chronic liver disease with small FLRs and no currently feasible treatment for postoperative liver failure, PVE is the only technique that may prevent fatal complications. Thus, there will never be any randomized, controlled trials for those with small liver remnants because to withhold this potential beneficial technique would be unethical.
Our standard criteria for major resection of HCC in patients with chronic liver disease are presented in Table 1 . We do incorporate clinically relevant increased portal pressure into our decision making for major resection in chronic liver disease. This is defined as presence of esophageal varices or a platelet count of \100,000/mm. Others have found that clinically relevant portal hypertension in the presence of abnormal liver function testing (i.e., high bilirubin levels) leads to far shorter survival and major postoperative morbidity due to decompensated liver failure. 43, 44 Furthermore, we do not offer extended hepatectomy to patients with evidence of chronic liver disease for similar reasons. In patients with hepatocellular injury (i.e., increase in aspartate aminotransferase) from active hepatitis, we have found that treatment with interferon in the weeks after PVE and before resection can be of benefit. For those patients without chronic liver disease in whom we anticipate extended right hepatectomy, we recommend embolization of segment 4 branches as well, because we have had improved post-PVE hypertrophy of segments 2/3 with this approach. 45 Furthermore, because the main blood supply for HCC is the hepatic artery, PVE results in increased hepatic arterial flow and, theoretically, accelerated tumor growth. As such, PVE can also be combined with TACE for additional benefit because TACE eliminates the arterial blood supply to the tumor and embolizes potential arterioportal shunts in cirrhotic livers that can attenuate the effects of PVE. This assumption is supported by previously reported data in which patients who undergo TACE before PVE have greatly increased FLR hypertrophy ([20%) as well as improved disease-free survival (up to 56%) than patients who underwent PVE alone. 46, 47 Such innovative measures allow the broadening of typical surgical indications and improve the safety of major hepatic resection.
Systemic Therapy
The use of multiagent systemic chemotherapy in an effort to downstage large or locally advanced HCC to allow resection has been attempted because single-agent regimens have had limited responses. 48 PIAF (cisplatin, interferon, doxorubicin, and fluorouracil) was used to treat selected locally advanced HCC. Fifteen (10%) of 149 patients with advanced HCC were successfully downstaged, with 8 of these patients found to have complete pathological tumor response. 49, 50 The 3-year survival was 53% for those who underwent surgical resection, and a better response to neoadjuvant chemotherapy was found in patients with less severe liver disease. Systemic therapy overall has little net benefit in terms of overall or diseasefree survival in most patients with potentially resectable HCC. Newer biological agents have also not been found to increase the response rates in advanced HCC, although a recent multicenter trial found that sorafenib, a small molecular inhibitor of several tyrosine protein kinases unique in targeting the Raf/Mek/Erk pathway (mitogenactivated protein kinase pathway), was found to greatly improve progression-free and overall survival. 51 However, none of these patients experienced enough response to permit resection. Overall, the role of various combinations of systemic, regional, and subsequent resection remains to be elucidated in advanced HCC.
OPERATIVE CONSIDERATIONS
Technique
Great advances have been made in operative technique for major liver resection such that overall mortality has greatly declined over the past two decades. Methods such as low central venous pressure anesthesia, portal inflow occlusion, vascular isolation, and numerous coagulating, dissecting, and stapling instrumentation have made excessive blood loss and the resulting need for transfusion with attendant decrease in long-term survival the exception rather than the rule. A recent review of our data looking at [1500 hepatic resections identified parenchymal transection technique as an independent risk factor for perioperative red cell transfusion, and the use of the twosurgeon technique (combined saline-linked cautery and ultrasonic dissection) was associated with a lower transfusion rate than other techniques. 52, 53 When discussing high-risk HCC, particularly large or multinodular cancers requiring extended resection in the presence of chronic liver disease, additional maneuvers are necessary to perform safe surgery in these patients. The anterior approach without mobilization of the right liver has been found to be associated with less blood loss (8.3% vs. 28.3%) as well as improved overall survival (68.1% vs. 22.6%), in a randomized, controlled trial. 54 Interestingly, however, this trial did not find differences in disease-free survival (16% and 14%), suggesting that this approach leads to better perioperative outcome as a result of lower perioperative mortality, but that the long-term oncologic benefit remains inconclusive. Our group has found that the liver-hanging maneuver, first described by Belghiti et al., allows direct exposure, balanced countertraction, and controlled hemostasis; this is our preferred approach in many of high-risk HCC. 55, 56 This technique allows for safe and complete resection of large and complex intra-and extrahepatic right upper quadrant tumors. It also allows total vascular exclusion after parenchymal transaction, and other advanced techniques, such as inferior vena cava resection and thrombectomy, are more easily and safely performed.
CONCLUSION
An increasing number of patients with HCC do not meet traditional criteria for standard therapies as a result of historically poor outcomes. These oncologically high-risk patients, who have large tumors, multinodular disease, or major vascular invasion, can selectively be offered aggressive surgical resection with acceptable outcomes. This requires adequate preoperative evaluation and multidisciplinary novel perioperative approaches that are best provided at hepatobiliary centers with specialized expertise.
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